Indeed, the activity of the key enzymes involved in NO production, namely ASS1, ASL, arginase and NOS, are frequently altered in various types of cancers, enabling us to identify vulnerabilities in NO-related pathways and to design novel anti-cancer drugs that target these enzymes. This evidence concerns the gene ASS1 and cancer.